Results in other studies found favorable responses to ICI therapy in BRAF mutant tumors, but equivalent survival to BRAF wild-type or NSCLC patient tumors with no driver mutations; however, specific BRAF variant types were not always included, many only examined the effects of ICI monotherapy, and/or correlation with variant type and PD-L1/TMB biomarkers was not examined with these cross-comparisons. This evidence concerns the gene CD274 and non-small cell lung carcinoma.